Dexilant
In brief
- In our pharmacy, you can buy Dexilant without a prescription, with delivery across the United Kingdom and discreet packaging available.
- Dexilant (dexlansoprazole) is used to treat gastro-oesophageal reflux disease (GERD) and erosive oesophagitis; it is a proton pump inhibitor that suppresses stomach acid by inhibiting the H+/K+ ATPase in gastric parietal cells and uses a dual delayed‑release system for prolonged acid control.
- Usual doses are 30 mg once daily for symptomatic GERD and maintenance, and 60 mg once daily for healing erosive oesophagitis (treatment durations commonly up to 4–8 weeks for healing and up to 6 months for maintenance); adolescents 12–17 years use the same doses as adults.
- The drug is administered orally as delayed‑release capsules (commonly 30 mg and 60 mg).
- Dexilant begins to reduce gastric acid within about 1 hour, with many patients noticing symptom improvement within 1–3 days; maximal effect may take several days of treatment.
- Each dose gives up to 24 hours of acid suppression due to the dual delayed‑release formulation; prescribed treatment courses vary (healing up to 8 weeks, maintenance up to 6 months).
- Avoid excessive alcohol — alcohol can worsen reflux symptoms and increase gastrointestinal side effects; it is advisable to limit alcohol while taking Dexilant.
- The most common side effect is diarrhoea; other common effects include nausea, abdominal pain, flatulence and headache.
- Would you like to try Dexilant without a prescription?
Basic Dexilant information
- INN (international nonproprietary name): Dexlansoprazole
- Brand names available in the United Kingdom: Dexilant (dexlansoprazole)
- ATC code: A02BC06 — drugs for acid‑related disorders; proton pump inhibitors
- Forms and dosages: Capsule; 30mg, 60mg; oral; blister strip and bottles; all forms are delayed‑release with a dual delayed gastric dissolution system
- Manufacturers in the United Kingdom: Takeda Pharmaceuticals
- OTC / Rx classification: Prescription-only medicine (POM)
Overview
Dexilant (INN: dexlansoprazole) is a branded delayed‑release proton pump inhibitor available as 30mg and 60mg capsules.
The dual delayed‑release formulation reduces strict meal timing compared with many other PPIs.
Product positioning — who Dexilant is for
Indications, age groups and clinical niches
Which patients are most likely to be prescribed Dexilant?
Dexilant is a prescription PPI used for symptomatic gastro‑oesophageal reflux disease (GERD) and for healing erosive oesophagitis in adults and adolescents aged 12 and older.
Typical clinical uses are short‑term healing of erosive disease and longer‑term maintenance to prevent relapse after healing.
- Erosive oesophagitis
- Induction: 60mg once daily for up to 8 weeks to promote mucosal healing.
- Maintenance therapy
- Maintenance: 30mg once daily for up to 6 months to reduce relapse risk.
- Symptomatic GERD
- Symptom control: 30mg once daily for up to 4 weeks for relief of heartburn and regurgitation.
- Adolescents
- Same dosing as adults for patients aged 12–17 years where indicated.
Ideal patient profile
- Frequent day and/or night‑time reflux symptoms not controlled by lifestyle measures.
- Confirmed erosive oesophagitis requiring healing therapy.
- Patients with irregular meal patterns or shift workers who would benefit from less meal‑dependent dosing.
- Adolescents aged 12 years or older with erosive disease.
- Those who have experienced adherence difficulties with meal‑timed PPIs.
Forms, packaging and storage
Forms and storage advice
Dexilant is supplied as delayed‑release capsules in 30mg and 60mg strengths.
Packaging commonly includes blister strips and bottles.
The original manufacturer is Takeda.
Store capsules below 30°C in a dry place and keep in the original packaging to protect from moisture.
| Form | Dose | Packaging | Route |
|---|---|---|---|
| Capsule (delayed‑release) | 30mg | Blister strip, bottles | Oral |
| Capsule (delayed‑release) | 60mg | Blister strip, bottles | Oral |
Advise patients to avoid exposure to excessive heat or moisture and not to freeze capsules.
Dosing regimens in practice
Standard doses, missed dose and overdose guidance
How should patients take Dexilant and what should they do if they miss a dose?
Symptomatic GERD and maintenance commonly use 30mg once daily.
Erosive oesophagitis healing typically uses 60mg once daily for up to 8 weeks followed by 30mg maintenance for up to 6 months.
Adolescents aged 12 and older follow the adult dosing recommendations.
| Condition | Dose | Duration |
|---|---|---|
| Erosive oesophagitis (healing) | 60mg once daily | Up to 8 weeks |
| Maintenance therapy | 30mg once daily | Up to 6 months |
| Symptomatic GERD | 30mg once daily | Up to 4 weeks |
Missed dose: take as soon as remembered unless it is almost time for the next dose; do not double up doses.
Overdose: seek emergency medical attention; there is no specific antidote and management is supportive.
Counsel on swallowability — capsules should be swallowed whole and not crushed unless advice from a clinician permits alternative administration.
How the dual delayed‑release formulation affects use
Mechanism simplified for patients and adherence benefits
What is “dual delayed‑release” and why does it matter?
Dexilant capsules use a dual delayed‑release system that produces two separate releases of dexlansoprazole along the gastrointestinal tract.
This results in prolonged acid suppression and less strict dependence on dosing relative to meals compared with many single‑release PPIs.
For patients this generally means fewer timing errors, better control of night‑time symptoms for some users and simpler adherence for those with irregular schedules.
| Phase | Approximate action |
|---|---|
| First release | Early absorption to reduce daytime acid peaks. |
| Second release | Delayed absorption to extend acid suppression into night-time hours. |
Short FAQ
- Can Dexilant be taken with or without food? — The dual release reduces strict meal dependency compared with many classic PPIs.
- Can the capsule be opened? — Do not crush or open the capsule without consulting a clinician; the formulation is designed for intact release.
- Will timing changes matter? — There is increased flexibility, but try to take the dose at roughly the same time each day for best adherence.
Contraindications and clinical cautions
Absolute and relative contraindications
Which conditions make Dexilant unsuitable or require extra caution?
| Absolute contraindications | Relative cautions |
|---|---|
| Hypersensitivity to dexlansoprazole, other PPIs, or excipients | Severe hepatic dysfunction — use lowest effective dose for moderate impairment; not recommended in severe impairment |
| Co‑administration with products containing rilpivirine (contraindicated) | History of osteoporosis or fracture risk — monitor bone health for prolonged high‑dose use |
| Acute severe hepatic impairment | Risk of masking gastric malignancy — investigate unexplained GI alarm symptoms before prolonged PPI therapy |
- Severe hepatic impairment
- Refers to marked reduction in liver function; Dexilant is not recommended in this setting due to lack of safety data.
- Moderate hepatic impairment
- Use the lowest effective dose and monitor clinically.
- Renal impairment
- No routine dose adjustment is required as primary metabolism is hepatic.
Adverse effects and monitoring
Common side effects and long‑term safety signals
What should patients expect and what should be monitored if use is prolonged?
Common adverse events reported include diarrhoea, nausea, abdominal pain and flatulence.
Headache and upper respiratory tract infections are occasional findings in trial and post‑marketing data.
Long‑term safety signals associated with prolonged PPI use include hypomagnesaemia and vitamin B12 deficiency, increased fracture risk with prolonged high‑dose therapy and a possible increased risk of Clostridioides difficile infection in extended courses.
For repeat or prolonged prescriptions consider baseline and periodic checks where clinically indicated, such as magnesium levels and assessment of B12 if symptomatic.
| Adverse event | Frequency | Notes |
|---|---|---|
| Diarrhoea | Common | Usually self‑limiting; report if persistent |
| Nausea | Common | Mild GI discomfort |
| Abdominal pain | Common | May resolve with continued use |
| Flatulence | Common | Generally mild |
| Headache | Occasional | Mild‑to‑moderate |
| Upper respiratory tract infection | Occasional | Noted more with long‑term use |
Advise patients to report persistent diarrhoea, severe abdominal pain or new neurological symptoms promptly.
Interactions and polypharmacy considerations
Key drug interactions
Which medicines need review?
Co‑administration with rilpivirine is contraindicated due to clinically significant interactions.
Drugs where absorption is pH‑dependent, such as atazanavir and certain antifungals, may be affected by acid suppression and require review.
Warfarin and other drugs metabolised by CYP enzymes should be monitored for potential interaction effects.
| Drug/class | Interaction risk | Recommended action |
|---|---|---|
| Rilpivirine (antiretroviral) | High — contraindicated | Do not co‑prescribe; contact prescriber |
| Atazanavir | Absorption reduced by increased gastric pH | Review regimen; consider alternatives |
| Warfarin | Possible altered INR | Monitor INR after initiation or change |
| Tacrolimus / Methotrexate | Potential interaction risk in polypharmacy | Pharmacist‑led reconciliation and prescriber liaison advised |
Always check for antiretrovirals, interacting antifungals, antiplatelet or anticoagulant therapy and other narrow therapeutic index drugs.
Legal status and availability in the UK
Dexilant (dexlansoprazole) is a prescription-only medicine (POM).
In our online pharmacy, Dexilant is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.
Counselling points
Key points at supply and follow‑up
- Confirm indication and intended duration of therapy before supply.
- Check for absolute contraindications such as hypersensitivity and concurrent rilpivirine.
- Confirm hepatic status and advise dose adjustments in moderate impairment.
- Counsel on administration: swallow capsules whole; do not chew or crush.
- Advise on missed dose and overdose procedures: do not double up; seek emergency care for overdose.
- Discuss long‑term risks such as magnesium/B12 deficiency and fracture risk with prolonged high‑dose use.
Dexilant compared with other PPIs
Most PPIs are therapeutically interchangeable for acid suppression, but Dexilant’s dual delayed‑release formulation can justify choice in specific patients, for example where adherence problems or night‑time symptom control are an issue.
| Feature | Dexilant (dexlansoprazole) | Omeprazole / esomeprazole / pantoprazole |
|---|---|---|
| Typical dose | 30mg / 60mg | Varies; omeprazole 20mg commonly used |
| Meal timing | More flexible due to dual release | Often requires dosing before meals for optimal effect |
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Leicester | England | 9–21 days |
| Coventry | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
Practical points
For patients worried about long‑term risks, discuss the lowest effective dose and the planned review date for any repeat prescription.
New or worsening GI alarm symptoms should be reported so that underlying conditions such as gastric malignancy can be ruled out before prolonged acid suppression.
